SAB Biotherapeutics, Inc. (SABS): Total Liabilities
$21.32M
As of 2025-12-31
$23.43M
As of 2026-06-30
+2.4%
3-year compound annual growth
+4.0%
5-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $21.32M | +17.0% | 2026-03-09, Balance as of period end |
| 2024-12-31 | $18.23M | -31.6% | 2026-03-09, Balance as of period end |
| 2023-12-31 | $26.64M | +34.2% | 2025-03-31, Balance as of period end |
| 2022-12-31 | $19.85M | n/a | 2024-03-29, Balance as of period end |
| 2022-06-30 | $22.29M | n/a | 2023-04-14, Balance as of period end |
| 2022-03-31 | $27.23M | n/a | 2023-04-14, Balance as of period end |
| 2021-12-31 | $42.59M | +143.0% | 2023-04-28, Balance as of period end |
| 2020-12-31 | $17.53M | n/a | 2023-04-28, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| SAB Biotherapeutics, Inc. (SABS) | 2025-12-31 | $21.32M | +17.0% |
| Sutro Biopharma, Inc. (STRO) | 2025-12-31 | $306.28M | -10.6% |
| Caribou Biosciences, Inc. (CRBU) | 2025-12-31 | $53.19M | -11.9% |
| Aura Biosciences, Inc. (AURA) | 2025-12-31 | $32.52M | +6.5% |
| Cabaletta Bio, Inc. (CABA) | 2025-12-31 | $53.03M | +62.1% |
| Inhibikase Therapeutics, Inc. (IKT) | 2025-12-31 | $8.30M | +122.3% |
| Vaxart, Inc. (VXRT) | 2025-12-31 | $98.28M | -8.5% |
| Editas Medicine, Inc. (EDIT) | 2025-12-31 | $159.25M | -23.2% |
| Neumora Therapeutics, Inc. (NMRA) | 2025-12-31 | $87.18M | +191.5% |
Compare SABS, STRO, CRBU, AURA side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗